ARQT vs TER · rev $196.5M vs P/E 76, rev $2.82B
Arcutis Biotherapeutics Inc (ARQT) versus Teradyne Inc (TER) — a side-by-side from cached financials, not a winner call.
Arcutis Biotherapeutics Inc (ARQT) is a biotechnology company listed on US.
Teradyne Inc (TER) is a semiconductor equipment & materials company listed on NASDAQ.
Latest reported ARQT revenue for 2024-12-31 was $196.5M. Net income was -$140.0M. Revenue was up 229.7% from 2023-12-31 to 2024-12-31. ARQT currently screens at market cap $1.64B.
Latest reported TER revenue for 2024-12-31 was $2.82B. Net income was $542.4M. Revenue was up 5.4% from 2023-12-31 to 2024-12-31. TER currently screens at market cap $63.96B and trailing P/E 75.7.
ARQT currently screens at market cap $1.64B. TER currently screens at market cap $63.96B and trailing P/E 75.7.
Not investment advice. Open the ARQT and TER stock pages for the full models.
Not investment advice.